The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSurgical Innovations Regulatory News (SUN)

Share Price Information for Surgical Innovations (SUN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.50
Bid: 0.40
Ask: 0.60
Change: 0.00 (0.00%)
Spread: 0.20 (50.00%)
Open: 0.50
High: 0.50
Low: 0.50
Prev. Close: 0.50
SUN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Distalmotion’s Dexter Robot receives CE Mark

8 Jan 2021 07:00

RNS Number : 9916K
Surgical Innovations Group PLC
08 January 2021
 

Surgical Innovations Group plc("Surgical Innovations", "SI" or the "Company")

 

Distalmotion's Dexter Robot receives CE Mark

 

Surgical Innovations Group plc (AIM: SUN), the designer, manufacturer and distributor of innovative medical technology for minimally invasive surgery ("MIS"), announces that Distalmotion SA, a Swiss-based medical device company providing robotic surgery systems on a transparent and fair per-procedure cost ("Distalmotion"), has received European CE Mark for its 'Dexter' surgical robot. Manufactured in Switzerland, Dexter combines the affordability of laparoscopy with the benefits of robotic surgery to bring simplicity and versatility in minimally invasive surgical care. 

 

Elemental Healthcare Limited, a wholly owned SI subsidiary, has exclusive UK distribution rights for the Dexter Robot.

 

The European CE mark remains valid in the UK post Brexit.

 

Adam Power, SI Group Development Director, commented: "The UK minimally invasive surgical robot market has been dominated by a single, expensive and very complex robot for nearly two decades. Dexter is designed to integrate readily into existing laparoscopic procedures and its simplicity and versatility makes robotics accessible for a wider range of procedures. The regulatory approval of the Dexter operating robot now allows the introduction of a disruptive robotic model to UK healthcare. The ease of use, affordability and Swiss manufacturing excellence will be significant factors in the growth opportunity for this new robot."

 

Michael Friedrich, CEO, Distalmotion said: "Distalmotion are looking forward to some early successes in the important UK market with our partner, Elemental Healthcare. The NHS is especially appropriate for the Dexter strategic model of selling and we already have hospitals that are some way into the process of product acquisition."

 

 

For further information please contact:

 

Surgical Innovations Group plc

www sigroupplc com

David Marsh, CEO

Tel: 0113 230 7597

Charmaine Day, Co Sec & GFC

 

 

 

N+1 Singer (Nominated Adviser & Broker)

Tel: 020 7496 3000

Aubrey Powell (Corporate Finance)

 

Rachel Hayes (Corporate Broking)

 

 

 

Walbrook PR (Financial PR & Investor Relations)

Tel: 020 7933 8780 or si@walbrookpr.com

Paul McManus / Lianne Cawthorne

Mob: 07980 541 893 / 07584 391 303

 

About Surgical Innovations Group plc

The Group specialises in the design, manufacture, sale and distribution of innovative, high quality medical products, primarily for use in minimally invasive surgery. Our product and business development is guided and supported by a key group of nationally and internationally renowned surgeons across the spectrum of minimally invasive surgical activity.

 

We design and manufacture and source our branded port access systems, surgical instruments and retraction devices which are sold directly in the UK home market through our subsidiary, Elemental Healthcare, and exported widely through a global network of trusted distribution partners. Many of our products in this field are based on a "resposable" concept, in which the products are part re-usable, part disposable, offering a high quality and environmentally responsible solution at a cost that is competitive against fully disposable alternatives.

 

Elemental also has exclusive UK distribution for a select group of specialist products employed in laparoscopy, bariatric and metabolic surgery, hernia repair and breast reconstruction.

In addition, we design and develop medical devices for carefully selected OEM partners, and have also collaborated with a major UK industrial partner to provide precision engineering solutions to complex problems outside the medical arena.

 

We aim for our brands to be recognised and respected by healthcare professionals in all major geographical markets in which we operate and provide by development, partnership or acquisition a broad portfolio of cost effective, procedure specific surgical instruments and implantable devices that offer reliable solutions to genuine clinical needs in the operating theatre environment.

 

The Group currently employs approximately 100 people across two sites in the UK. Product design, engineering and manufacturing are carried out at the SI site in Yorkshire. Commercial activities including marketing, UK distribution and international sales and marketing are based at Elemental Healthcare in Berkshire.

 

Further information

Further details of the Group's businesses are available on the following websites:

www.sigroupplc.com

www.surginno.com 

www.elementalhealthcare.co.uk

To receive regular updates by email, please contact si@walbrookpr.com.

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAFLFLDLDIDIIL
Date   Source Headline
4th Jun 201811:34 amRNSHolding(s) in Company
25th May 20187:00 amRNSTrading Update
23rd Mar 20183:25 pmRNSDirector/PDMR Shareholding
13th Mar 20183:06 pmRNSDirector/PDMR Shareholding
13th Mar 20187:00 amRNSFinal Results
28th Feb 20187:00 amRNSDistribution agreement via Elemental Healthcare
19th Feb 20187:01 amRNSDistribution agreement via Elemental Healthcare
19th Feb 20187:00 amRNSNotice of Results
11th Jan 20187:00 amRNSYear-end trading update
21st Dec 201712:15 pmRNSIssue of Shares
15th Nov 201711:47 amRNSDirector/PDMR Shareholding
6th Nov 20177:00 amRNSDirector/PDMR Shareholding
31st Oct 201710:58 amRNSDirector/PDMR Shareholding
31st Oct 20177:00 amRNSGrant of Options
30th Oct 20172:33 pmRNSIssue of Equity
10th Oct 20173:36 pmRNSIssue of Equity
26th Sep 201712:28 pmRNSIssue of Equity
22nd Sep 20178:55 amRNSHolding(s) in Company
13th Sep 20177:00 amRNSHalf-year Report
10th Aug 20177:00 amRNSNotice of Results
4th Aug 201712:32 pmRNSNotification of Major Interest in Shares
3rd Aug 20179:30 amRNSNotification of Major Interest in Shares
2nd Aug 20171:31 pmRNSNotification of Major Interest in Shares
1st Aug 20174:48 pmRNSNotification of Major Interest in Shares
1st Aug 20178:07 amRNSAcquisition, PDMR Dealings and Directorate Changes
28th Jul 20177:00 amRNSDirector/PDMR Shareholdings
27th Jul 201710:53 amRNSResult of Equity Issue
27th Jul 20177:00 amRNSProposed Acquisition, Placing and Subscriptions
30th Jun 20175:07 pmRNSHolding(s) in Company
30th Jun 20175:05 pmRNSHolding(s) in Company
26th Jun 20172:40 pmRNSResult of AGM
26th Jun 201710:45 amRNSIssue of Shares
26th Jun 20177:00 amRNSAGM Statement
5th Jun 20174:24 pmRNSAnnual Report & Accounts and Notice of AGM
11th Apr 20179:03 amRNSDirector/PDMR Shareholding
3rd Apr 201711:26 amRNSDirector/PDMR Shareholding
28th Mar 20177:00 amRNSDirector/PDMR Shareholding
27th Mar 20177:00 amRNSIssue of Shares
14th Mar 20177:00 amRNSFinal Results
1st Mar 20177:00 amRNSNotice of Results
9th Jan 20177:00 amRNSYear-end trading update
22nd Dec 20167:00 amRNSRevised Banking Facilities
21st Dec 20167:00 amRNSConversion of Loan Notes & Issue of Shares
20th Dec 20167:00 amRNSDirector's responsibilities
21st Nov 20167:00 amRNSSite visit
7th Nov 20167:00 amRNSAcquisition
2nd Nov 20161:40 pmRNSDirector/PDMR Shareholding
26th Oct 20167:00 amRNSCE Certification for YelloPort Elite®
30th Sep 20167:00 amRNSIssue of Shares
31st Aug 20167:00 amRNSHalf-year Report

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.